INTRODUCTION
============

Gastric cancer remains one of the most common causes of cancer related death worldwide and the predicted incidence for 2010 is over one million as expected in previous reports. Gastric malignancies also show extensive tumor invasion and early spread to either regional lymph nodes or distant sites^[@B1]-[@B4]^ and this aggressive stance gives rise to the challenging questions about the way of the preoperative management strategies.

The stage oriented management of gastric cancer is one of the recent proposals and it is crucial to improve the outcome of patients with operable gastric cancer.^[@B5]-[@B7]^ Currently, preoperative staging relies on imaging studies. None of the available imaging modalities is sufficient to reliably confirm the presence or the number of regional lymph node metastasis and are inefficient to guide a clinical decision depending on nodal status.^[@B8]^

Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) are commonly used markers for gastric cancer.^[@B9]^ Although both markers are often measured in patients with gastric cancer preoperatively, the clinical correlation between CEA and CA 19-9 is reported as unclear and controversial.^[@B10]-[@B12]^ In addition to these common used markers; carbohydrate antigen 125 (CA 125) and carbohydrate antigen 72-4 (CA 72-4) have been reported to be elevated in advanced gastric cancer.^[@B13]^

Tumor markers have shown little benefit as a method for screening in the general population due to their low sensitivity and specificity in detecting early primary tumor, however, they can be used clinically for the monitoring of tumor recurrence and used as prognostic factors because higher levels have been observed in advanced disease.^[@B14]-[@B16]^ With respect to controversial reports about the impact of tumor markers on the management of gastric cancer, we aimed to investigate the relationship between the preoperative tumor marker levels and different clinical aspects of gastric cancer.

METHODS
=======

This study was approved by local ethics committee and we got written informed consent from all subjects included in this study. Between January 2009 and January 2012, 106 consecutive patients with confirmed diagnosis of gastric cancer and 106 subjects (age and sex matched) with no malignancy as control group were included prospectively in this study. The subjects in control group were selected from the group of patients with no determined malignancy (underwent gastroscopy and / or colonoscopy, abdominal computed tomography for different reasons and having no malignant or premalignant findings in their history, physical and diagnostic examinations).

The exclusion criteria were operation history of any malignancy, having any malignancy except gastric cancer, already being a smoker, having pancreatitis. Patients' mean age was 61.3 years (range 31-91 years); 71 were males and 35 were females.

Routine preoperative evaluation protocol of our departments consisted of clinical examination, gastroscopy and colonoscopy if indicated for clinical suspicion, abdominal computed tomography, chest radiography and computed tomography for thorax if indicated and serum levels of CEA, CA 19-9 and CA 125. We aimed to evaluate only preoperative tumor marker levels in relation with different clinical or histopathological aspects of gastric cancer. Blood samples were obtained at least one week before surgery for patient group. Serum CEA, CA 19-9 and CA 125 levels were determined with the upper limit of normal defined as 5ng/ml for CEA, 38U/ml for CA 19-9 and 35U/ml for CA 125.

The relationships between tumor markers CEA, CA 19-9 and stage of disease (with respect to American Joint Committee on Cancer, gastric cancer staging, TNM), tumor differentiation (grade), presence of ringlet cell type, presence of peritoneal carcinomatozis were investigated.

IBM^®^ The Statistical Package for Social Sciences (SPSS^®^) version 20 software was used for statistical analysis of data. All values were expressed as median (minimum- maximum). After the homogeneity tests; non -- parametric tests (Mann -- Whitney and Kruskal -- Wallis tests) were used for statistical evaluation and p\<0.05 was accepted as the level of significance.

RESULTS
=======

There was no statistical difference between serum CA 19-9 levels of gastric cancer patients and controls (p=0.103). On the other hand; the serum CEA and CA 125 levels were found to be significantly elevated in gastric cancer patients than in controls (p\<0.001 for both) ([Table-I](#T1){ref-type="table"}).

The serum tumor marker levels of patients didn\'t show any significant difference according to either T stage or N stage of the disease (p\>0.05 for all markers) ([Table-II](#T2){ref-type="table"}). The serum level of CEA had showed a significant elevation with the presence of distant metastasis (M1) (p=0.019) ([Table-II](#T2){ref-type="table"}).

The CA 19-9 and CA 125 levels had showed significant elevations where the CEA levels showed no significance with the presence of peritoneal carcinomatozis (p=0.007, p=0.018 and p=0.644 respectively) ([Table-III](#T3){ref-type="table"}). There was no significant difference between serum tumor marker levels of patients with respect to tumor grade or the presence of ringlet cell type of tumor cells.

DISCUSSION
==========

The increased levels of tumor markers such as CEA and CA 19-9 are proposed to be correlated with clinic and pathological features of gastric cancer.^[@B17]-[@B20]^ In clinical practice; the tumor markers CEA and CA 19-9 are used to assess the efficacy of adjuvant treatment as a supplementary evidence for response.^[@B21],[@B22]^ Despite numerous reports on the usefulness of preoperative and periodic postoperative CEA measurements to predict stage,^[@B23]^ tumor progression,^[@B24]^ recurrence^[@B25]-[@B27]^ and prognosis^[@B10],[@B28],[@B29]^ in patients with gastric cancer, already tumor markers have limited clinical utility due to their low sensitivity and specificity.^[@B30]-[@B32]^ The positive rate of serum CEA and CA 19-9 at the initial diagnosis of gastric cancer has been reported to be 11.8%-37% ^[@B33]-[@B37]^ and 18%-45% ^[@B22],[@B37]^ respectively. Although serum CA 19-9 levels had showed no significant difference between gastric cancer patients and controls in our study, the serum levels of CEA and CA 125 were found to be significantly elevated in patients than controls. The available data from previous studies confirm that the conventional tumor markers such as CEA and CA 19-9 don\'t allow diagnosis of gastric cancer with adequate sensitivity and specificity.^[@B21],[@B38]^

###### 

Tumor marker levels. Patients vs. Controls

  ------------------------------------------------------------------------------
                   *Median (Minimum-Maximum)*    \                     
                                                *p*                    
  ---------------- ---------------------------- ---------------------- ---------
  CA 19-9 (U/ml)   15 (0.8 - 4047)              10.96 (0.17 -- 24.5)   0.103

  CEA (ng/ml)      1.79 (0.05 -- 51.43)         1.1 (0.03 -- 5.01)     \<0.001

  CA 125 (U/ml)    11.6 (0.6 -- 171.7)          6.9 (1,2 -- 68.4)      \<0.001
  ------------------------------------------------------------------------------

###### 

Tumor marker levels with respect to TNM staging. (CA 19-9: U/ml, CEA: ng/ml, CA 125: U/ml).

  ----------------------------------------------------------------------------------------------------------------------
       Median (Minimum -- Maximum)                                                                              
  ---- ----------------------------- ---------------------- --------------------- ------- --------------------- --------
  T1   9.85 (0.8 -- 14,8)             \                     2.07 (0.7 -- 5.8)      \      7.95 (5.77 -- 23.3)    \
                                     0.188                                        0.795                          0.737

  T2   20.26 (10 -- 79,9)            1.44 (0.5 -- 10)       12.08 (7.6 -- 54)                                   

  T3   16.99 (0.8 -- 700)            1.99 (0.64 -- 14.7)    11.4 (1 -- 49.6)                                    

  T4   15.15 (1.2 -- 4047)           1.81 (0.05 -- 51.43)   12.4 (0.6 -- 171.7)                                 

  N0   10.61 (0.8 -- 40.78)           \                     1.7 (0.28 -- 11.02)    \      9.85 (1-54)            \
                                     0.067                                        0.802                          0.282

  N1   18.2 (6.95 -- 700)            1.33 (0.33 -- 10.94)   18.9 (2.5 -- 171.7)                                 

  N2   17.1 (1.2 -- 3765)            1.99 (0.1 -- 51.43)    13.4 (2.6 -- 43.6)                                  

  N3   14.56 (0.8 -- 245)            1.93 (0.05 -- 35.5)    10.15 (4.1 -- 94)                                   

  M0   15 (0.8 -- 4047)              0.073                  1.64 (0.05 -- 35.5)    \      11.6 (0.6 -- 171.7)    \
                                                                                  0.019                         0.827

  M1   15.8 (1.2 -- 614.18)          4.98 (0.13 -- 51.43)   11.7 (2.6 -- 125.4)                                 
  ----------------------------------------------------------------------------------------------------------------------

###### 

Tumor marker levels with the presence of peritoneal carcinomatozis

  -------------------------------------------------------------------------------
                   Peritoneal Carcinomatozis    \                         
                                               p                          
  ---------------- --------------------------- -------------------------- -------
  CA 19-9 (U/ml)   14,21 (0.8 -- 4047)         579,92 (14,11 -- 614,18)   0.007

  CEA (ng/ml)      1,81 (0.05 -- 51,43)        1,67 (0.13 -- 34,56)       0.644

  CA 125 (U/ml)    11,3 (0.6 -- 171,7)         19,7 (13,4 -- 125,4)       0.018
  -------------------------------------------------------------------------------

In a previous study by Ishigami et al;^[@B38]^ it is reported that serum CEA and CA 19-9 levels are significantly and positively correlated with the depth of invasion, nodal involvement, cure possibility and distant metastasis. Our results showed that there is no significant difference correlated with depth of invasion (T stage) and lymph node involvement (N stage). However, the serum level of CEA had showed a significant elevation with the presence of distant metastasis (M1 patients). In the view of combined CEA and CA 19-9 positivity, the positivity of CEA and/or CA 19-9 may reflect biologic malignant properties such as lymphatic spread or distant metastasis.^[@B12],[@B14],[@B38]^ Although some studies proposed that there appears to be clinical significance in detecting CEA and CA 19-9, some studies express doubt to confirm this way of management.^[@B10]-[@B12],[@B39]^ The positivity of CEA and CA 19-9 was significantly correlated with TNM stage, depth of invasion and lymph node metastasis in a more recent study.^[@B40]^ Despite the numerous reports on the usefulness of preoperative and postoperative CEA measurements to predict stage,^[@B23]^ tumor progression,^[@B24]^ recurrence^[@B25]^ or prognosis;^[@B28]^ there is no agreement as to what kinetics of change is likely to be significant and over what period of time such a change should be maintained for significance.^[@B41]^ The positivity of CEA in the presence of distant metastasis may be explained with the direct role of CEA by acting like an adhesion molecule in invasion and metastasis so the cancer cells producing CEA have more chance of metastasis.^[@B42],[@B43]^

Peritoneal dissemination is frequent and life threatening form of metastasis and recurrence in patients with gastric cancer. Intraperitoneal chemotherapy has been shown to have a considerable positive effect on peritoneal dissemination. Although the systemic chemotherapy has been shown to prolong the survival of gastric cancer patients, there is a lack of complete success.^[@B44]-[@B46]^ Serum CA 125 levels are known to be elevated in peritoneal inflammation and in carcinomatozis^[@B47],[@B48]^ and a significant relationship between CA 125 and gastric cancer with peritoneal dissemination has been reported.^[@B49]-[@B51]^ The CA 19-9 and CA 125 levels had showed significant elevations with the presence of peritoneal carcinomatozis in our study. The presence of ascites, level of ascites and the degree of peritoneal metastasis are not correlated with CEA and CA 19-9; however they have a significant correlation with CA 125 positivity.^[@B44]^ The serum level of CA 125 was reported to be more sensitive in combination with other tumor markers such as CA 19-9 for peritoneal dissemination.^[@B44]^

Some authors have tried to explain the low sensitivity of tumor markers in their studies in terms of the histology of the tumor, with the diffuse type of gastric cancer presenting the lowest positivity rate of the tumor markers. On the other hand, some previous reports made this hypothesis controversial with the higher positivity rate of CEA, CA 72-4 and CA 19-9 in the diffuse type of gastric cancer.^[@B38],[@B52]^ Our results showed that there was no significant difference between serum tumor marker levels of patients with respect to tumor grade or the presence of ringlet cell type of tumor cells. It is also shown that no correlation between tumor marker levels and the histology of gastric cancer.^[@B14]^

As a conclusion; there seems to be many controversial and conflicting reports about the relationship of tumor markers and the clinical properties of gastric cancer. Our results also showed that there is a limited clinical benefit of preoperative tumor marker measurements in gastric cancer such as estimation of peritoneal dissemination. The various types of biological behaviors of gastric cancer need further studies on molecular basis of tumor cells and tumor markers.
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